------------------------------------------------------------
Doxorubicin + Dacarbazine (AD)
DOXORUBICIN 60 mg/m2/day C.I. DAYS 1-5
DACARBAZINE 1,000 mg/m2/day C.I. DAYS 1-4
Repeat cycle Q21 days
------------------------------------------------------------
CyVADIC (Soft Tissue Sarcoma)
Cyclophosphamide 500 mg/m2 IVB day 1
Vincristine 1 mg/m2 IVB* days 1 & 5
Doxorubicin 50 mg/m2 IVB day 1
Dacarbazine 250 mg/m2 IV/1h days 1-5
Repeat cycle every 21 days.
*Maximum vincristine dose is 2 mg.
Ref: Yap B, et al: Cancer Treat Rep 64:93 (1980).
------------------------------------------------------------
MAID
Mesna 2500 mg/m2 IV days 1-4
Doxorubicin 20 mg/m2 IV days 1-3
Ifosfamide 2500 mg/m2 IV days 1-3
Dacarbazine 300 mg/m2 IV days 1-3
Note: All drugs are administered by continuous infusion, doxorubicin is mixed with dacarbazine, and ifosfamide is mixed with mesna. Repeat treatment every 21 days.
Ref: Elias A, Ryan L, Sulkes A, et al; J Clin Oncol 7:1208-1216, 1989.
------------------------------------------------------------
A-DIC
Note: Where a dose range is given, the flowsheet
uses the lowest value.
Doxorubicin 45 - 60 mg/m2 IVB day 1
Dacarbazine 200-250 mg/m2 IV/1h days 1-5
Repeat cycle every 3 weeks.
Ref: Baker LH, et al: J Clin Oncol 5:851 (1987).
Borden EC, et al: J Clin Oncol 5:840 (1987).
------------------------------------------------------------
____________________________________________________________
Ewing's Sarcoma
------------------------------------------------------------
CyVADIC - 2
Cyclophosphamide 600 mg/m2 IVB day 1
Vincristine 1.4 mg/m2 IVB* weekly X 6
then 1.4 mg/m2 IVB* day 1 each cycle
Doxorubicin 15 mg/m2 CIV days 1-4
Dacarbazine 250 mg/m2 CIV days 1-4
OR
Doxorubicin 22.5 mg/m2 CIV days 1-4
Dacarbazine 225 mg/m2 CIV days 1-4
Repeat cycle every 21 to 28 days for 18 months.
*Maximum vincristine dose is 2 mg.
At total doxorubicin dose (450 mg/m2), substitute dactinomycin 2 mg/m2 on day 1 of each cycle.
Ref: Benjamin RS: In RT Skeel (ed):Handbook of Chemotherapy, Boston, Little Brown, p 203 (1987).
------------------------------------------------------------
NCI Web Site for Adult Soft-tissue Sarcoma NCI Web site for Ewing's Sarcoma NCI web site for Osteosarcoma ___________________________________________________ How to Distinguish PNET & Ewing’s from other small round cell tumors? The monoclonal antibody, HBA71, recognizes a cell-surface glycoprotein (p30/32MIC2) in human Ewing’s sarcoma & PNET. The strong immunoreactivity of HBA71 in Ewing’s sarcoma & PNET distinguishes these tumors from other small round cell tumors of childhood & adolescence. ___________________________________________________ PROGNOSTIC FACTORS: Patients with retroperitoneal, head and neck, and visceral sarcomas have a worse overall prognosis than do patients with extremity tumors. High-risk patient with extremity soft-tissue sarcoma: an individual with a large ( >5 cm), high-grade, deep lesion. Unlike other solid tumors, the adverse prognostic factors for local recurrence of a soft-tissue sarcoma differ from those that predict distant metastasis & tumor-related mortality. ___________________________________________________ Notes on treatment: 1. TNF-based isolated limb perfusion (ILP) appears to be an effective option for limb salvage in patients with locally advanced extremity soft-tissue sarcoma. REF= Eggermont AMM et al: Proc Am Soc Clin Oncol 18:535a [abstract], 1999. 2. XRT for inoperable tumors: Radiation doses should be at least 65-70 Gy. 5-year survival rates of 25%-40% with local control rates of 30% have been reported. 3. ADJUVANT XRT. Radiation therapy is always combined with surgical resection in the management of extremity soft-tissue sarcomas. No advantage for pre-op XRT. In fact, more wound complications noted! Limb-sparing surgery + postoperative XRT produces comparable local control rates to those achieved with amputation. 5-yr local control rates of 70%-90%, survival rates of 70%, & limb preservation rates of 85% can be expected. Therefore, Adjuvant XRT should be employed for virtually all high-grade extremity sarcomas & larger (>5 cm) low-grade lesions. If small (T1) lesions can be resected with clear margins, XRT can be omitted
|